In people with diabetic kidney disease, the use of SGLT2 inhibitor medications is similar between those on low-carbohydrate diets and those on low-calorie diets, and does not explain why kidney function declined at similar rates in both groups.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review could determine whether the effect of low-carbohydrate diets on eGFR decline is consistent across populations with and without SGLT2 inhibitor use.
A systematic review and meta-analysis of all studies reporting eGFR slope in adults with type 2 diabetes and eGFR 30–45 mL/min/1.73m² on low-carbohydrate diets, stratified by SGLT2 inhibitor use, with pooled estimates of slope differences and interaction testing.
An RCT could determine whether low-carbohydrate diets affect eGFR decline independently of SGLT2 inhibitor use.
A 2×2 factorial RCT of 300 adults with type 2 diabetes and eGFR 30–45 mL/min/1.73m², randomized to low-carbohydrate vs. standard diet and SGLT2 inhibitor vs. placebo, with eGFR slope as primary outcome over 4 years, to test diet and medication main and interaction effects.
A prospective cohort could confirm whether diet-related eGFR trajectories remain similar regardless of SGLT2 inhibitor use in real-world settings.
A prospective cohort study of 500 Japanese adults with type 2 diabetes and eGFR 30–45 mL/min/1.73m², stratifying by dietary pattern and SGLT2 inhibitor use, with annual eGFR measurements and adjustment for medication initiation timing.
A case-control study could assess whether SGLT2 inhibitor use differs between those with stable vs. declining eGFR on low-carbohydrate diets.
A case-control study comparing 100 adults with type 2 diabetes and eGFR decline >0.5 mL/min/year on low-carbohydrate diets to 200 matched controls with stable eGFR, assessing prior SGLT2 inhibitor use and duration.
A cross-sectional study could identify whether SGLT2 inhibitor use is associated with dietary pattern at a single time point.
A cross-sectional analysis of 700 Japanese adults with type 2 diabetes and eGFR 30–45 mL/min/1.73m², measuring current SGLT2 inhibitor use and dietary intake via food records to compare prevalence between low-carbohydrate and standard diet groups.